Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections.
Identifieur interne : 001948 ( PubMed/Checkpoint ); précédent : 001947; suivant : 001949Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections.
Auteurs : S L Stramer [États-Unis]Source :
- ISBT science series [ 1751-2816 ] ; 2014.
Abstract
In August 2009, a group from the AABB (Stramer et al., Transfusion 2009;99:1S-29S, Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety; http://www.aabb.org/resources/bct/eid/Pages/default.aspx) published a Supplement to Transfusion that reviewed emerging infectious disease (EID) agents that pose a real or theoretical threat to transfusion safety, but for which an existing effective intervention is lacking. The necessary attributes for transfusion transmission were outlined including: presence of the agent in blood during the donor's asymptomatic phase, the agent's survival/persistence in blood during processing/storage, and lastly that the agent must be recognized as responsible for a clinically apparent outcome in at least a proportion of recipients who become infected. Without these attributes, agents are not considered as a transfusion-transmission threat and were excluded. Sixty-eight such agents were identified with enough evidence/likelihood of transfusion transmission (e.g., blood phase) and potential for clinical disease to warrant further consideration. In the Supplement, Fact Sheets (FS) were published providing information on: agent classification; disease agent's importance; clinical syndromes/diseases caused; transmission modes (including vectors/reservoirs); likelihood of transfusion transmission, and if proven to be transfusion-transmitted, information on known cases; the feasibility/predicted success of interventions for donor screening (questioning) and tests available for diagnostics/ adapted for donor screening; and finally, the efficacy, if known, of inactivation methods for plasma-derived products. The Supplement included a separate section on pathogen reduction using published data. Agents were prioritized relative to their scientific/epidemiologic threat and their perceived threat to the community including concerns expressed by the regulators of blood. Agents given the highest priority due to a known transfusion-transmission threat and severe/fatal disease in recipients were the vCJD prion, dengue viruses and the obligate red-cell parasite that causes babesiosis (B. microti and related Babesia). Although the focus of the Supplement was towards the United States and Canada, many of the agents (and the process) are applicable worldwide.
DOI: 10.1111/voxs.12070
PubMed: 25210533
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25210533Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections.</title><author><name sortKey="Stramer, S L" sort="Stramer, S L" uniqKey="Stramer S" first="S L" last="Stramer">S L Stramer</name><affiliation wicri:level="2"><nlm:affiliation>American Red Cross Gaithersburg, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>American Red Cross Gaithersburg, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25210533</idno><idno type="pmid">25210533</idno><idno type="doi">10.1111/voxs.12070</idno><idno type="wicri:Area/PubMed/Corpus">001851</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001851</idno><idno type="wicri:Area/PubMed/Curation">001851</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001851</idno><idno type="wicri:Area/PubMed/Checkpoint">001948</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001948</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections.</title><author><name sortKey="Stramer, S L" sort="Stramer, S L" uniqKey="Stramer S" first="S L" last="Stramer">S L Stramer</name><affiliation wicri:level="2"><nlm:affiliation>American Red Cross Gaithersburg, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>American Red Cross Gaithersburg, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">ISBT science series</title><idno type="ISSN">1751-2816</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In August 2009, a group from the AABB (Stramer et al., Transfusion 2009;99:1S-29S, Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety; http://www.aabb.org/resources/bct/eid/Pages/default.aspx) published a Supplement to Transfusion that reviewed emerging infectious disease (EID) agents that pose a real or theoretical threat to transfusion safety, but for which an existing effective intervention is lacking. The necessary attributes for transfusion transmission were outlined including: presence of the agent in blood during the donor's asymptomatic phase, the agent's survival/persistence in blood during processing/storage, and lastly that the agent must be recognized as responsible for a clinically apparent outcome in at least a proportion of recipients who become infected. Without these attributes, agents are not considered as a transfusion-transmission threat and were excluded. Sixty-eight such agents were identified with enough evidence/likelihood of transfusion transmission (e.g., blood phase) and potential for clinical disease to warrant further consideration. In the Supplement, Fact Sheets (FS) were published providing information on: agent classification; disease agent's importance; clinical syndromes/diseases caused; transmission modes (including vectors/reservoirs); likelihood of transfusion transmission, and if proven to be transfusion-transmitted, information on known cases; the feasibility/predicted success of interventions for donor screening (questioning) and tests available for diagnostics/ adapted for donor screening; and finally, the efficacy, if known, of inactivation methods for plasma-derived products. The Supplement included a separate section on pathogen reduction using published data. Agents were prioritized relative to their scientific/epidemiologic threat and their perceived threat to the community including concerns expressed by the regulators of blood. Agents given the highest priority due to a known transfusion-transmission threat and severe/fatal disease in recipients were the vCJD prion, dengue viruses and the obligate red-cell parasite that causes babesiosis (<i>B. microti</i> and related <i>Babesia</i>). Although the focus of the Supplement was towards the United States and Canada, many of the agents (and the process) are applicable worldwide.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">25210533</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1751-2816</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>ISBT science series</Title><ISOAbbreviation>ISBT Sci Ser</ISOAbbreviation></Journal><ArticleTitle>Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections.</ArticleTitle><Pagination><MedlinePgn>30-36</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In August 2009, a group from the AABB (Stramer et al., Transfusion 2009;99:1S-29S, Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety; http://www.aabb.org/resources/bct/eid/Pages/default.aspx) published a Supplement to Transfusion that reviewed emerging infectious disease (EID) agents that pose a real or theoretical threat to transfusion safety, but for which an existing effective intervention is lacking. The necessary attributes for transfusion transmission were outlined including: presence of the agent in blood during the donor's asymptomatic phase, the agent's survival/persistence in blood during processing/storage, and lastly that the agent must be recognized as responsible for a clinically apparent outcome in at least a proportion of recipients who become infected. Without these attributes, agents are not considered as a transfusion-transmission threat and were excluded. Sixty-eight such agents were identified with enough evidence/likelihood of transfusion transmission (e.g., blood phase) and potential for clinical disease to warrant further consideration. In the Supplement, Fact Sheets (FS) were published providing information on: agent classification; disease agent's importance; clinical syndromes/diseases caused; transmission modes (including vectors/reservoirs); likelihood of transfusion transmission, and if proven to be transfusion-transmitted, information on known cases; the feasibility/predicted success of interventions for donor screening (questioning) and tests available for diagnostics/ adapted for donor screening; and finally, the efficacy, if known, of inactivation methods for plasma-derived products. The Supplement included a separate section on pathogen reduction using published data. Agents were prioritized relative to their scientific/epidemiologic threat and their perceived threat to the community including concerns expressed by the regulators of blood. Agents given the highest priority due to a known transfusion-transmission threat and severe/fatal disease in recipients were the vCJD prion, dengue viruses and the obligate red-cell parasite that causes babesiosis (<i>B. microti</i> and related <i>Babesia</i>). Although the focus of the Supplement was towards the United States and Canada, many of the agents (and the process) are applicable worldwide.</AbstractText><AbstractText Label="NEXT STEPS" NlmCategory="UNASSIGNED">Since the publication of the Supplement, six new FSs (yellow fever viruses-including vaccine breakthrough infections, miscellaneous arboviruses, XMRV, human parvoviruses/bocaviruses other than B19, and most recently the Middle East respiratory syndrome coronavirus, MERS-CoV) were added and 14 existing FSs updated (Anaplasma, Babesia, Bartonella, Erhlichia, chronic wasting disease-CWD, human prions other than vCJD, vCJD, <i>Coxiella burnetii</i>-the agent of Q fever, dengue viruses, HAV, HEV, Japanese encephalitis-JE complex, tick-borne encephalitis viruses-TBEV, and human parvovirus B19). Also, tables were released outlining pathogen reduction clinical trials/results (published) and availability/commercial routine use of such technologies by country. Of necessity, the list of EID agents is not, and can never be, complete due to the nature of emergence. We recognized that a system of assessing the risk/threat of EIDs for their potential impact on blood safety and availability must include processes for monitoring, identifying, evaluating, estimating severity, assessing risk and developing interventions. Thus, a 'toolkit' containing the necessary 'tools' from EID monitoring (horizon scanning) to validation/effectiveness evaluations of interventions is being developed. The goal is, to develop a systematic approach to risk assessment and intervention development for the impact of emerging infectious upon blood safety intended to educate and provide advise about risks/interventions in a timely/accurate fashion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The process and final product (toolkit) including methods to monitor EID agent emergence, identification/recognition of a transfusion-transmission threat, methods for quantitative risk assessments, and the appropriate management of such threats should be considered for implementation by all blood systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stramer</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>American Red Cross Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>ISBT Sci Ser</MedlineTA><NlmUniqueID>101296348</NlmUniqueID><ISSNLinking>1751-2816</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">blood donation testing</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">transfusion</Keyword><Keyword MajorTopicYN="N">transmissible infections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25210533</ArticleId><ArticleId IdType="doi">10.1111/voxs.12070</ArticleId><ArticleId IdType="pmc">PMC4142007</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>Transfusion. 2012 Aug;52(8):1647-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22304614</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2013 Oct;53(10 Pt 2):2505-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23829163</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367 (19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood Transfus. 2008 Oct;6(4):199-210</Citation><ArticleIdList><ArticleId IdType="pubmed">19112735</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Aug;52(8):1634-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22882092</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2013 Dec;19(12):2034-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24274664</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2012 Aug;52(8):1657-66</Citation><ArticleIdList><ArticleId IdType="pubmed">22339201</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2013 Jul;53(7):1421-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23113823</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2008 Jul;48(7):1333-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18298600</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2013 Oct;53(10 Pt 2):2567-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23176378</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013 Aug 01;18(31):null</Citation><ArticleIdList><ArticleId IdType="pubmed">23929229</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2013 Oct;53(10 Pt 2):2375-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23926897</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Apr 25;496(7446):504-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Jul;3(7):e263</Citation><ArticleIdList><ArticleId IdType="pubmed">16700631</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2012 May;18(5):869-72</Citation><ArticleIdList><ArticleId IdType="pubmed">22516170</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2011 Dec;17(12):2309-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22172156</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Biol Sci. 2008 Sep 22;275(1647):2111-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18505720</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2013 Sep 27;62(38):793-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24067584</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Rev. 2010 Jan;24(1):15-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19962571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2011 May;140(5):1481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21354150</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Feb 21;451(7181):990-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18288193</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Aug;49 Suppl 2:1S-29S</Citation><ArticleIdList><ArticleId IdType="pubmed">19686562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Stramer, S L" sort="Stramer, S L" uniqKey="Stramer S" first="S L" last="Stramer">S L Stramer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001948 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001948 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25210533
|texte= Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25210533" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |